Factor this: Evaluating Current Blood Factor Use at Henry Ford Health

Document Type

Conference Proceeding

Publication Date

1-8-2025

Publication Title

Am J Health Syst Pharm

Abstract

Purpose: Exogenous blood factors are indispensable therapies for managing patients with hemophilia, treating traumatic bleeding events, and controlling bleeding disorders. These therapies are also associated with significant cost and patient associated risks, including further bleeding complications or thrombotic events. Optimizing use of these products is vital given their complexity, patient associated adverse events, and costs. Given the limited data available, a better understanding of blood factor use is essential for both patients and their care teams. The purpose of this study is to describe the current practices and identify opportunities for improvement of blood factor use at Henry Ford Health. Methods: This IRB-approved multi-site, retrospective, observational study includes patients who are 18 years of age or older and had an order placed for blood factor product from January 1, 2021 to August 1, 2024 at any Henry Ford Health acute care hospital, emergency department, or procedural area. Patients will be excluded if they received Prothrombin Complex Concentrate (KCentra®), received blood factors for anticoagulation reversal, or if they were incarcerated at the time of their hospital encounter. A randomized convenience sample of 75 patients that meet the pre-specified inclusion and exclusion criteria during the defined study period will be included. Data will be collected through the electronic health record database and documented on a standardized case report form. Primary outcomes of interest include appropriate product selection and dosing regimens based on evidence-based medicine or consult service recommendations. Other outcomes of interest include rates of bleeding events, thrombotic complications and costs. Descriptive statistics with measures of central tendency will be used to analyze the data. This will be characterized through means and standard deviations or medians and interquartile ranges, as appropriate. Continuous variables will be expressed as proportions and prevalence rates. The results of the study are expected to provide a clearer description of the current practices around blood factor use and identify opportunities for improvement at Henry Ford Health.

Volume

82

First Page

S989

Find It @ Sladen

Share

COinS